India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.

US off-patent industry association the AAM has blasted as unconstitutional a groundbreaking California law banning so-called ‘pay-for-delay’ deals under which brand companies pay rivals to keep generics off the market.

Indian credit rating agency ICRA has forecast that the country’s pharmaceutical industry will remain on a steady 11%-13% growth path this fiscal year, underpinned by healthy domestic demand, new launches and market share gains.

India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”

A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.

Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.